1. Home
  2. BSVN vs FULC Comparison

BSVN vs FULC Comparison

Compare BSVN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank7 Corp.

BSVN

Bank7 Corp.

N/A

Current Price

$43.72

Market Cap

416.1M

Sector

Finance

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$6.57

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSVN
FULC
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.1M
467.8M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
BSVN
FULC
Price
$43.72
$6.57
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$53.67
$16.38
AVG Volume (30 Days)
6.2K
538.1K
Earning Date
04-14-2026
04-27-2026
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
1.25
N/A
Revenue
N/A
N/A
Revenue This Year
$5.05
N/A
Revenue Next Year
$4.05
N/A
P/E Ratio
$34.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.91
$5.88
52 Week High
$50.10
$15.74

Technical Indicators

Market Signals
Indicator
BSVN
FULC
Relative Strength Index (RSI) 57.99 42.50
Support Level $42.02 $6.36
Resistance Level $45.58 $7.09
Average True Range (ATR) 0.73 0.38
MACD 0.01 -0.03
Stochastic Oscillator 100.00 42.59

Price Performance

Historical Comparison
BSVN
FULC

About BSVN Bank7 Corp.

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: